InhA-IN-11 

InhA-IN-11 is a Mycobacterium tuberculosis InhA inhibitor with an IC₅₀ of 0.36 μM. InhA-IN-11 exhibits activity against Mycobacterium tuberculosis, disrupts pre-formed Mycobacterium tuberculosis biofilms, and reduces bacterial viability within biofilms. InhA-IN-11 is applicable for the research of tuberculosis^[1].

InhA-IN-11 (Compound 6) at 0.5 μg/mL potently inhibits the growth of extracellular Mycobacterium tuberculosis H37Rv, with an MIC of 0.5 μg/mL^[1].
InhA-IN-11 (40-50 μg/mL; 168-336 h) exhibits bactericidal activity against Mycobacterium tuberculosis H37Rv^[1].
InhA-IN-11 (5 μg/mL; 48 h) effectively kills Mycobacterium tuberculosis H37Rv within human monocyte-derived macrophages^[1].
InhA-IN-11 (50 μg/mL; 48 h) disrupts preformed Mycobacterium tuberculosis H37Rv biofilms and reduces bacterial viability^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

304.37

C₁₄H₁₆N₄O₂S

CCOC(C1=C(N=C(S1)N/N=C(C2=CC=CC=N2)\C)C)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Sabt A, et al. Investigation of Potent Anti-Mycobacterium tuberculosis Agents Derived from Pyridine Derivatives Targeting the Enoyl Acyl Carrier Protein Reductase (InhA): Design, Synthesis, and Computational Analysis. Drug Design, Development and Therapy. 2026 Dec 31:1-7.